The results of the current study, which focused on a number of individual components of clinical response, demonstrated that patients with ET who are refractory to or intolerant of hydroxyurea can achieve clinically meaningful and durable reductions in platelet and WBC counts and improvements in ET-related symptoms with ruxolitinib treatment.
Scheda prodotto non validato
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
Titolo: | Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. | |
Autori: | ||
Data di pubblicazione: | 2017 | |
Rivista: | ||
Abstract: | The results of the current study, which focused on a number of individual components of clinical response, demonstrated that patients with ET who are refractory to or intolerant of hydroxyurea can achieve clinically meaningful and durable reductions in platelet and WBC counts and improvements in ET-related symptoms with ruxolitinib treatment. | |
Handle: | http://hdl.handle.net/11571/1321726 | |
Appare nelle tipologie: | 1.1 Articolo in rivista |
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.